Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Evusheld

- PMLiVE

MIT researchers design more powerful RNA vaccines for COVID-19

The new type of RNA vaccine was shown to produce a stronger immune response at a lower dose

- PMLiVE

AstraZeneca shares positive phase 3 results for Tagrisso combination in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

Moderna’s updated COVID-19 vaccine shows strong effect against BA.2.86 subvariant

The ‘highly mutated’ BA.2.86 subvariant is being closely monitored by global health authorities

- PMLiVE

NHS England to bring forward flu and COVID-19 vaccine programmes

The change follows an announcement on the risks presented by the new BA.2.86 COVID-19 variant

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine recommended by CHMP

Doses will be ready to ship immediately upon authorisation by the European Commission

- PMLiVE

AstraZeneca latest to sue US government over Medicare drug price negotiation plan

The programme already faces court challenges from drugmakers and industry groups

- PMLiVE

US government awards $1.4bn for development of COVID-19 vaccines and therapeutics

The funding includes a contract with Regeneron for a next-generation antibody therapy

- PMLiVE

Novavax’s updated COVID-19 vaccine candidate shows promise against emerging subvariants

The protein-based vaccine generated immune responses against the fast-spreading ‘Eris’ strain

- PMLiVE

NHS to initiate flu vaccine roll-outs for children from September

The roll-outs are part of the NHS winter flu and COVID-19 vaccination programme

- PMLiVE

World Health Organization classifies EG.5 as a COVID-19 ‘variant of interest’

The strain accounted for over 17% of COVID-19 cases between 17 and 23 July

- PMLiVE

JCVI announces advice for autumn COVID-19 booster vaccine eligibility

The Committee has advised offering the booster to those at high risk of serious disease

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody backed by CDC advisory committee for infants

Beyfortus will be available in the US ahead of the upcoming RSV season

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links